Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.
The next stock on our list is Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX).
TheFly reported on Feb 11 that JP Morgan raised AMRX price target by $4 and maintained a Buy rating.
Separately, on January 29, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced that it would be added to the S&P SmallCap 600 Index. It is a popular benchmark for U.S. small-cap stocks and is composed of businesses that satisfy certain standards for sector balance, market size, liquidity, and long-term profitability. The corporation claims that its participation demonstrates consistent operational execution and financial performance. The management of the company thinks that being included in the index will increase its visibility to investors, potentially improve trading liquidity, and ultimately result in more shareholders.
Furthermore, KeifeRx and Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) inked a research collaboration and option agreement on January 9 to develop KFRX06, which is a preclinical candidate that targets the gene leucine-rich repeat kinase 2 (LRRK2). It is closely linked to Parkinson’s disease. As per the agreement, KeifeRx will lead research efforts to produce essential pre-IND data that will aid Amneal in assessing the program and guide potential future development decisions. The detailed financial details of the arrangement were not disclosed to the public.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a U.S. pharmaceutical company that develops, manufactures, and markets generic and specialty branded medicines across multiple therapeutic areas, emphasizing cost‑effective access, innovation in complex formulations, and scalable supply solutions for patients and healthcare providers.
While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
Disclosure: None.
